These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Chang YJ; Zhao XY; Huang XJ Front Immunol; 2018; 9():3041. PubMed ID: 30619371 [TBL] [Abstract][Full Text] [Related]
3. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study. van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM Front Immunol; 2020; 11():1804. PubMed ID: 32973756 [TBL] [Abstract][Full Text] [Related]
4. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Jones SC; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217 [TBL] [Abstract][Full Text] [Related]
6. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach. Sinkovics JG Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421 [TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
8. New developments in allotransplant immunology. Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790 [TBL] [Abstract][Full Text] [Related]
9. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation. Hadjis AD; McCurdy SR Front Immunol; 2024; 15():1358668. PubMed ID: 38817602 [TBL] [Abstract][Full Text] [Related]
10. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia. Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532 [TBL] [Abstract][Full Text] [Related]
11. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558 [TBL] [Abstract][Full Text] [Related]
12. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. Ghosh A; Koestner W; Hapke M; Schlaphoff V; Länger F; Baumann R; Koenecke C; Cornberg M; Welte K; Blazar BR; Sauer MG Blood; 2009 Apr; 113(18):4440-8. PubMed ID: 19182207 [TBL] [Abstract][Full Text] [Related]
13. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Weisdorf DJ; Nelson G; Lee SJ; Haagenson M; Spellman S; Antin JH; Bolwell B; Cahn JY; Cervantes F; Copelan E; Gale R; Gratwohl A; Khoury HJ; McCarthy P; Marks DI; Szer J; Woolfrey A; Cortes-Franco J; Horowitz MM; Arora M; Biol Blood Marrow Transplant; 2009 Nov; 15(11):1475-8. PubMed ID: 19822308 [TBL] [Abstract][Full Text] [Related]
15. The potential role of γδ T cells after allogeneic HCT for leukemia. Handgretinger R; Schilbach K Blood; 2018 Mar; 131(10):1063-1072. PubMed ID: 29358176 [TBL] [Abstract][Full Text] [Related]
16. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370 [TBL] [Abstract][Full Text] [Related]
17. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210 [TBL] [Abstract][Full Text] [Related]
18. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation. Russell CA Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093 [TBL] [Abstract][Full Text] [Related]
19. Which donor or graft source should you choose for the strongest GVL? Is there really any difference. Weisdorf D Best Pract Res Clin Haematol; 2013 Sep; 26(3):293-6. PubMed ID: 24309533 [TBL] [Abstract][Full Text] [Related]
20. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Fowler DH; Gress RE Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]